Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2023-08-04 Board/Management Inform…
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Trading Window
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges informing about an upcoming Board Meeting scheduled for August 9, 2023. The purpose of the meeting includes considering changes in the composition of the Board of Directors due to share acquisition. It also mentions the closure of the insider trading window around the meeting date. The document is a notification about a board meeting and insider trading window closure, not the actual report or minutes of the meeting. It is a regulatory announcement related to board/management changes but does not itself announce the changes, only the meeting to consider them. Therefore, it fits best under 'Board/Management Information' (MANG) as it relates to board composition changes and insider trading window notices, which are typical for such filings. The document length is short and does not contain financial data or detailed report content, so it is not an Annual Report or Interim Report. Confidence is high due to clear references to board meeting and insider trading window closure related to board changes.
2023-08-04 English
Intimation of Board Meeting and Insider Trading window close.
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges informing about a scheduled Board Meeting to consider changes in the composition of the Board of Directors due to share acquisition. It also mentions the closing of the insider trading window around the meeting date. The document is short (1927 characters) and serves as an announcement of an upcoming board meeting and insider trading window closure, not the actual report or minutes of the meeting. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-08-04 English
Updates
Major Shareholding Notification Classification · 95% confidence The document is an official intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details the sale of a significant shareholding (33.38%) by a promoter to another company, including specifics of the share purchase agreement, transaction terms, and impact on management control. It also references compliance with SEBI regulations related to substantial acquisition of shares and takeovers. The document is a disclosure of a major shareholding change and related transaction, not a full financial report or earnings release. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is a detailed disclosure, not a brief announcement or a report publication notice.
2023-08-02 English
Update on sale of shares by promoter to Ipca Laboratories Ltd.
Major Shareholding Notification Classification · 100% confidence The document is an official intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details the sale of a significant shareholding (33.38%) by a promoter to another company, including specifics of the share purchase agreement, approval by the Competition Commission of India, and the impact on management control. The document includes disclosures required by SEBI for substantial acquisition of shares and takeover regulations. It is not a financial report, earnings release, or management discussion but a regulatory announcement about a major shareholding change and control transfer. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive disclosure under regulatory requirements.
2023-08-02 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Prakash A Mody
Director's Dealing Classification · 100% confidence The document is a formal disclosure by Dr. Prakash A. Mody regarding the sale of a substantial portion of his shares in Unichem Laboratories Limited. It references compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, which pertains to disclosures of share dealings by promoters or substantial shareholders. The content includes detailed shareholding percentages before and after the transaction, the mode of sale, and dates. This is a clear example of a Director's Dealing or insider transaction disclosure rather than a financial report, earnings release, or other corporate filings. The document length and detail support it being a full disclosure rather than a brief announcement. Therefore, the appropriate classification is Director's Dealing (DIRS).
2023-08-02 English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ipca Laboratories Ltd
Regulatory Filings
2023-08-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.